Motivation: Therapeutic enhancement of innate immune response to microbial attack is addressed as the optimal control of a dynamic system. Interactions between an invading pathogen and the innate immune system are characterized by four non-linear, ordinary differential equations that describe rates of change of pathogen, plasma cell, and antibody concentrations, and of an indicator of organic health. Without therapy, the dynamic model evidences sub-clinical or clinical decay, chronic stabilization, or unrestrained lethal growth of the pathogen; the response pattern depends on the initial concentration of pathogens in the simulated attack. In the model, immune response can be augmented by therapeutic agents that kill the pathogen directly, that stimulate the production of plasma cells or antibodies, or that enhance organ health. A previous paper demonstrated open-loop optimal control solutions that defeat the pathogen and preserve organ health, given initial conditions that otherwise would be lethal (Stengel et al., 2002) . Therapies based on separate and combined application of the agents were derived by minimizing a quadratic cost function that weighted both system response and control usage, providing implicit control over harmful side effects. Results: We demonstrate the ability of neighboringoptimal feedback control to account for a range of unknown initial conditions and persistent input of pathogens by adjusting the therapy to account for perturbations from the nominal-optimal response history. We examine therapies that combine open-loop control of one agent with closedloop control of another. We show that optimal control theory points the way toward new protocols for treatment and cure of human diseases.
INTRODUCTION
Infectious microbes trigger a dynamic response of the immune system, in which potentially uncontrolled growth of the invader (or pathogen) is countered by various * To whom correspondence should be addressed. protective mechanisms. The outer perimeter of defense consists of the surface epithelial layers of the body, including the epidermal cells of the skin and the mucosal cells that line the respiratory, gastrointestinal, and genitourinary tract (Lydyard et al., 2000; Janeway, 2001; Thain and Hickman, 2000) . The innate immune system provides a tactical response, signaling the presence of 'non-self' organisms and activating B cells to produce antibodies that bind to the intruders' antigens. The antibodies identify targets for scavenging cells (e.g. neutrophils and macrophages) that engulf and consume the microbes, reducing them to non-functioning units. They also stimulate the production of cytokines, complement, and acutephase proteins that either damage an intruder's plasma membrane directly or that trigger the second phase of immune response. The innate immune system protects against many extracellular bacteria or free viruses found in blood plasma, lymph, tissue fluid, or interstitial space between cells, but it cannot defeat microbes that burrow into cells, such as viruses, intracellular bacteria, and protozoa.
Strategic response to intracellular microbial assault is provided by the adaptive immune system, which produces protective cells that remember specific antigens, that produce antibodies to counter the antigens, and that seek out epitopes (or defining regions) of antigens on the surfaces of infected cells. Adaptive immune mechanisms depend on the actions of B and T lymphocyte cells that become dedicated to a single antibody type through clonal selection. Killer T cells (or cytotoxic T lymphocytes) bind to infected cells and kill them by initiating programmed cell death (apoptosis). Helper T cells assist naive B cells in maturing into plasma cells that produce the needed antibody type. Immune cells with narrowly focused memory are generated, ready to respond rapidly if invading microbes with the same antigen epitopes are encountered again. Elements of the innate and adaptive immune systems are shared, and response mechanisms are coupled, even though separate modes of operation can be identified.
Here, we address post-exposure therapy for a clinically diagnosed condition. The options available for clinical treatment of infection once it has been recognized focus on killing the invading microbes, neutralizing their deleterious effects, enhancing the efficacy of immune response, and providing palliative or healing care to other organs of the body. Few biological or chemical agents have just a single effect; for example, an agent that kills a virus also may damage healthy 'self' cells. A critical function of drug discovery and development is to identify new compounds that have maximum intended efficacy with minimal side effects in the general population. Examples include antibiotics as microbe killers; interferons as microbe neutralizers; interleukins, antigens from killed (i.e. non-toxic) pathogens, and pre-formed and monoclonal antibodies as immunity enhancers (each of very different nature); and anti-inflammatory and anti-histamine compounds as palliative drugs.
Many models of immune response to infection have been postulated (Asachenkov et al., 1994; Rundell et al., 1995; Perelson, 1997; Nowak and May, 2000) , with recent emphasis on the human-immunodeficiency virus (HIV; Nowak et al., 1995; Perelson et al., 1996; Perelson and Nelson, 1999; Wodarz et al., 2000a,b; Stafford et al., 2000) . Norbert Wiener (Wiener, 1948) and Richard Bellman (Bellman, 1983) appreciated and anticipated the application of mathematical analysis to treatment in a broad sense, and Swan (1981) surveys early optimal control applications to biomedical problems. Kirschner et al. (1997) offers an optimal control approach to HIV treatment, and intuitive control approaches are presented in Bonhoeffer et al. (1997) ; Wein et al. (1998) ; Wodarz and Nowak (1999) and Wodarz and Nowak (2000) . The dynamics of drug response (pharmacokinetics) are modeled in van Rossum et al. (1986) and Robinson (1986) , and control theory is applied to drug delivery in Bell and Katusiime (1980) ; Carson et al. (1985) ; Chizeck and Katona (1985) ; Schumitsky (1986); Jelliffe (1986); Polycarpou and Conway (1996) ; Kwong et al. (1996); Gentilini et al. (2001) and Parker et al. (1996) .
The present analysis examines regimens for applying drugs in a manner that maximizes efficacy while minimizing side effects and cost. That means killing, neutralizing, or limiting growth of the pathogen with small impact on the patient's health and pocketbook. By illustrating optimal enhancement of immune response, control theory can help discriminate between options for attacking the disease directly, stimulating the immune system, suppressing or amplifying ancillary biological processes, prescribing drug dosage and timing, and specifying multiple-drug therapies.
In the remainder, we present a simple model for the response of the innate immune system to infection and to therapy, review the prior method and results of optimization (Stengel et al., 2002) , and introduce a significant extension to the optimal control method of enhancing immune response. The earlier results show not only the progression from an initially life-threatening state to a controlled or cured condition but the optimal history of therapeutic agents that produces that condition. Here, the therapeutic method is extended by adding linear-optimal feedback control to the nominal optimal solution. Perturbations from the expected history of immune state may arise from uncertainty about the initial concentration of pathogen or the continuing introduction of new pathogen. Feedback allows the therapy to be adjusted, expanding the range of infectious intensity that can be treated effectively and efficiently.
A MODEL OF NATURAL AND ENHANCED IMMUNE RESPONSE
A simple model of infectious disease is presented in Asachenkov et al. (1994) for the principal purpose of 'studying the general picture of the course of a disease and clarifying some observational results.' There are four components to the model's dynamic state:
x 1 = concentration of a pathogen that expresses a specific foreign antigen; x 2 = concentration of plasma cells that are specific to the foreign antigen; x 3 = Concentration of antibodies that bind to the foreign antigen;
x 4 = characteristic of a damaged organ [0 = healthy, 1 = dead].
In Asachenkov et al. (1994) , the first element of the state is loosely referred to as a concentration of 'viruses', by which is meant a concentration of pathogenic antigens; however, too many elements of the adaptive immune system (most notably helper and killer T cells in various states of activation or infection) are missing for the model to represent response to a viral attack. Nevertheless, the Asachenkov model does characterize qualitative behavior of the innate immune system, and we view x 1 as a concentration of extracellular bacteria that are 'virulent. ' We add idealized therapeutic control agents, u i , as well as an exogenous input, w, to the model of Asachenkov et al. (1994) , where: u 1 = pathogen killer; u 2 = plasma cell enhancer; u 3 = antibody enhancer; u 4 = organ healing factor (or health enhancer); w = rate of continuing introduction of pathogen.
The structural relationship of system variables is illustrated by Figure 1 . Introduction of the pathogen stimulates the production of plasma cells and antibodies and degrades organ health. Organ health mediates plasma cell production, inferring a relationship between immune response and fitness of the individual. Antibodies bind to the attacking antigens, thereby killing pathogenic microbes directly, activating complement proteins, or triggering an attack by phagocytic cells, e.g. macrophages and neutrophils. Each element of the state is subject to independent control, and new microbes may continue to enter the system.
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where the x i vary with time, except for the steady equilibrium value of x 2 *, which is 2. Values of the parameters used for this study are: a 11 = a 12 = a 23 = a 31 = a 42 = b 2 = b 3 = 1, b 1 = b 4 = −1, a 22 = 3, a 32 = 1.5, and a 33 = a 41 = 0.5. a 21 (x 4 ) is a nonlinear function that describes the mediation of plasma cell generation by the damaged organ:
The parameters have been chosen to produce a system that recovers or succumbs to the pathogen (without treatment) as a function of initial conditions during a period of ten time units. Both parameters and time units are abstractions, as no specific disease is addressed. The state and control are always positive because concentrations cannot go below zero, and organ death is indicated when x 4 = 1. Figure 2 (from Stengel et al., 2002) shows typical uncontrolled response to increasing levels of initial pathogen concentration. Conceptually, the sub-clinical response would not require medical examination, while the clinical case warrants medical consultation but is self-healing without intervention. Pathogen concentration stabilizes at non-zero value in the chronic case, which is characterized by permanently degraded organ health, and it diverges in the lethal case, killing the organ. The 'lethal' simulation of Figure 2 is allowed to continue past the point at which x 4 exceeds one for illustrative purposes only. The mathematical model is seen to have a stable equilibrium when x = 0 and a neutrally stable equilibrium in the neighborhood of the chronic solution at the end of the period.
TREATMENT COST FUNCTION AND THE NOMINAL-OPTIMAL CONTROL POLICY
The model of Equations (1-4) allows us to simulate innate immune response to pathogenic attack and to therapy, but it does not tell us what the therapeutic protocol should be. The optimal therapeutic protocol is derived by minimizing a treatment cost function, J , that penalizes large values of pathogen concentration, poor organ health, and excessive application of therapeutic agents over the fixed time interval [t 0 , t f ] and at the end of the treatment interval:
The cost function variables are squared to amplify the effects of large variations and to de-emphasize contributions of small variations. Each squared element is multiplied by a coefficient ( p ii , q ii , or r ii ) that establishes the relative importance of the factor in the treatment cost. These coefficients could reflect financial cost, or they could represent physiological 'cost,' such as virulence, toxicity, or discomfort. The weighting coefficients provide a mechanism for trading one variation against the others in defining the treatment protocol, balancing speed and efficacy of treatment against implicit side effects. The disease dynamic model (Equations 1-4) can be expressed in vector form,
where x is the state, u is the control, and w is an exogenous disturbance. The scalar cost function (Equation 6) takes the general form,
, t] is called the Lagrangian, and the p ii , q ii , and r ii are diagonal elements of the matrices P, Q, and R.
Defining the Hamiltonian of the system,
the necessary conditions for optimizing the cost function with respect to control are expressed by the three Euler-Lagrange equations (Stengel, 1994) : u(t), w(t), λ(t) , t] ∂u .
In scalar form, the equations arė
The Euler-Lagrange equations include a linear, ordinarydifferential equation whose integral is the adjoint vector, λ(t) (Equation 10), a terminal boundary condition that specifies λ(t f ) at the end of the interval (Equation 11), and a stationarity condition on the control throughout the interval (Equation 12). Here, the disturbance, w(t), is treated as a known parameter. Equations (7) and (10-12) must be satisfied concurrently, specifying a two-point boundary-value problem that is solved numerically. The solution is necessarily iterative because the system model is non-linear, initial conditions are given for x, and terminal conditions are given for λ. The solution is initiated by solving Equation (7) with a starting guess for the control history, u o (t) in [t 0 , t f ]. Equation (10) is solved, integrating back from the end conditions specified by Equation (11). In general, the remaining necessary condition for optimality, Equation (12), is not satisfied, so a steepest-descent method is used to generate successive approximations of the optimal control history u * (t) from
where c is a small positive constant and k is the iteration index (Stengel et al., 2002) . For k sufficiently large, ∂ H/∂u tends to zero, and u(t) converges to the optimal control history that is applied in Equations (1-4) or (7). Nominal-optimal solutions computed for otherwiselethal initial conditions and unit cost function weights are presented in Figure 3 (from Stengel et al., 2002) . Finding the control history that minimizes the cost function typically requires 10-20 steepest-descent iterations. The example shows that each of the therapeutic agents used separately can defeat the pathogen and maintain organ health with varying (but important) participation of the innate immune system. All of the therapeutic protocols specify an initially strong dose of the agent followed by exponential decay. These results infer that combination therapies can be even more effective in defeating the pathogen and maintaining organ health than treatment by a single agent, and the present neighboring-optimal approach confirms the inference.
While the drug concentration decays over time in Figure 3 , this is not a pharmacokinetic effect, as the model contains no dynamics of drug uptake. The reduction in therapeutic level is prescribed by the optimization procedure alone. If the drug is consumed or eliminated at a rate greater than that shown in the figure, then additional dosage is required to maintain the level prescribed by the optimization.
If the initial concentration of pathogen is changed from its nominal value, the nominal-optimal therapy is no longer optimal, and a new regimen must be defined to retain optimality. For small increase in initial pathogen concentration, the combination of the innate immune system and the nominal-optimal control policy prevails, and the pathogen is defeated, though the response history is no longer optimal. For a strong enough assault, the combination of immune response and therapy is insufficient, and the pathogen grows without bound, killing the organ. The therapeutic protocol must be adjusted to accommodate the change, either through continued reevaluation of the nominal-optimal policy or through a simpler mechanism for modifying the policy in proportion to deviations from the expected response history. In the remainder of the paper, we show that linear-optimal feedback control provides a good mechanism for adjusting the therapy, and it provides a simple means for introducing additional therapeutic agents that are not included in the nominal-optimal protocol.
NEIGHBORING-OPTIMAL CONTROL POLICY
Enhancement of the optimal therapy can be based on the solution of a neighboring-optimal control problem, as presented in Stengel (1994) and elsewhere. Actual state and control histories can always be represented as sums of the optimal histories derived from the iterative procedure, x * (t) and u * (t), and deviations from those histories, x(t) and u(t),
Neglecting the disturbance effect, Equation (7) can be expanded as,
where F(t) and G(t) are the time-varying Jacobian matrices evaluated along the nominal-optimal history. Because the nominal-optimal solution satisfies Equation (7), the dynamics of the perturbed state are closely approximated by the linear, time-varying equation
when perturbations are small deviations from the nominal solution. This equation can be written explicitly as
Optimal histories for this model of perturbed response are derived from the same conditions as before (Equations 10-12), but we redefine the cost function and Hamiltonian as functions of the perturbation variables. The new cost function is the second variation of the original cost function,
and the Hamiltonian is expressed as,
where λ(t) is the adjoint vector for the linearized system. The Euler-Lagrange equations (Equations 10-12) can be applied to the variational system described by . From Equation (12), the control perturbation can be expressed as
Furthermore, the terminal condition for the adjoint vector (Equation 11) is of the form,
and as λ and x are adjoint, eq. 21 applies over the entire interval. Because Equations (10) and (17) are linear, ordinary differential equations, the neighboring optimization is subject to a linear dynamic constraint (Equation 17), and the optimal control policy is a linear feedback control law (Stengel, 1994) :
C(t) is the time-varying optimal gain matrix given by,
and P(t) is the solution to a matrix Riccati equation (Stengel, 1994) :
The dimensions of all matrices follow from the original problem specification. Thus, the feedback gain matrix, C(t), is calculated just once for the nominal-optimal therapeutic history. From Equations (14) and (15), the optimal control policy accounts for previously unknown initial condition perturbations in the form
where x(t) is the state measured at the time therapy is applied, x * (t) is its nominal-optimal value, and u(t) is the total therapy applied at time t. The optimal treatment protocol is prescribed by the nominal-optimal control history, the time-dependent gain matrix, and the difference between the observed response and the nominal-optimal response.
APPLICATION TO ENHANCED IMMUNE RESPONSE
To illustrate the effect of nominal-plus neighboring-optimal therapy, we first compute nominal-optimal treatment for a given initial concentration of pathogen, then increase the infectious load to a point where the no-longer-optimal therapy fails. The effects of neighboring-optimal control are then shown. Holding the initial pathogen concentration at its original value, we also consider a case with a continuing influx of the infectious agent. The effects of singleand multi-agent feedback therapies are demonstrated for the more stressing cases.
Single-agent therapies
Our previous study (Stengel et al., 2002) revealed that the pathogen killer, u 1 , and antibody enhancer, u 3 , were the most effective individual controls, so we focus on those two here. The cost-function weighting matrices, Q and R, are the same for both the nominal and neighboring optimizations. Except as noted, Q is an identity matrix, Fig. 4 . Comparision of control responses with nominal and increased initial concentrations of pathogen. Nominal initial pathogen with nominal-optimal control (dash), increased initial pathogen with nominal-optimal control (dot-dash), and increased initial pathogen with nominal-optimal plus neighbouring-optimal control (solid) of pathogen killer (u 1 ).
the diagonal term of R corresponding to the single control is one, and all other elements of R are zero.
The effects of treatment with the pathogen killer alone are shown in Figure 4 . The nominal therapy, u 1 * (t), controls the pathogen and preserves organ health with the assumed initial pathogen concentration but not with the increased microbial assault. The principal reasons for failure are that the therapy decays exponentially with time and the damage to the organ allows the antibody concentration to drop off as well. Adding the neighboringoptimal control
to the nominal-optimal control, u 1 * (t), produces a response that parallels the original one. The additional infusion of u 1 provides a stronger response to the pathogen and preserves antibody concentration. Maximum degradation of organ health is larger, but health eventually is restored. The feedback gains that provide this beneficial effect are also shown in the figure. The predominant (and lasting) effect is possible feedback of pathogen concentration to pathogen killer through c 11 , though there is also a small continuing feedback of organ health through c 14 . All of the gains possess a two-time-unit transient near the beginning of the history.
Basing the therapy on antibody enhancer alone, u 3 * (t), produces similar nominal and off-nominal results ( Figure 5 ; see Internet supplement). The response with neighboring-optimal control, given by u 3 (t) = u 3
is successful in defeating the pathogen, but only if we ignore the fact that the organ health indicator briefly reaches one, signifying organ death. Had the initial condition been slightly smaller or the cost-function weight on organ health been higher, the treatment would have succeeded. The response is generally slower than that of the previous case, and build-up of both plasma cells and antibodies is greater than before. Plasma cell and antibody concentrations evidence a secondary response that begins after five time units. The intensity of feedback effect can be increased by decreasing the cost function weight on control, r 33 , which increases control gains, quickening the response and preserving long-term organ health (not shown). Nevertheless, the feedback gains all approach zero over time, precluding lasting protection without redefining the control solution.
Combined therapies
It is straightforward to compute the nominal-optimal history using one control variable and the neighboringoptimal control law using another. In such a case, the cost function control weighting matrices, R, for the two solutions are not the same. We examine some combined therapies based upon the pathogen killer, antibody enhancer, and organ health enhancer. The response and control gains are like those of the previous case when nominal-optimal pathogen killer is combined with neighboring-optimal antibody enhancer or when the nominal control is antibody enhancer, and the feedback control is pathogen killer (Figure 6 and 7; see Internet supplement). The net responses of these two cases are quite similar, though the control profiles and gains differ. While the organ is not killed in either case, the cost function weight on organ health (q 44 ) could be increased to widen the margin between ill health and organ death.
Feedback enhancement of organ health is unsuccessfully combined with nominal-optimal enhancement of antibodies (Figure 8 ; see Internet supplement). The effect of u 4 on the pathogen is indirect, stimulating organ health, which enhances plasma cell production, which enhances antibody production, which kills the pathogen. Antibody concentration does not increase enough to prevent runaway of the infection, and the organ is quickly killed. Examining the feedback gains, we see that the control is insensitive to the pathogen perturbation (via c 41 ) until it is too late to make a difference.
A much better result is obtained when the penalty on organ health enhancer use is reduced (r 44 = 0.1) and that feedback control is combined with nominal-optimal pathogen killer ( Figure 9 ; see Internet supplement). The feedback gains now recognize the importance of the pathogen petrubation and mount an early defense. Although plasma cell and antibody petrubations have a negligible effect on the feedback control, both of their concentrations remain strong throughout the episode. Furthermore, the direct effect of u 4 on the rate of change of x 4 prevents its excursion from being much worse than in the nominal-optimal case.
Response to continuing infection
We may anticipate circumstances in which infection is characterized not only by a large initial concentration at the beginning of a treatment period but by the continuing re-infection of microbes sequestered in regions not directly modeled by Equations (1-4). As a preliminary look at this problem, we add a constant disturbance of w = 0.5 to the simulation and return to single-agent control with the pathogen killer. The nominal-optimal control is computed for w = 0, but the feedback gains are computed for a second optimal history that assumes w = 0.5. Thus, the gains are not the same as those shown in Figure 4 . Applying the nominal-optimal control to the disturbed system results in divergence, even though the initial infection is unchanged (Figure 10 ; see Internet supplement). The characteristic loss of antibodies and organ degradation are apparent. Neighboring-optimal control prevents the divergence, and system response is nearly nominal. The feedback control senses the continuing intrusion and injects a bias control that effectively cancels it. As a consequence, both plasma cells and antibodies are kept at higher levels, adding to the defense.
CONCLUSION
There are compelling reasons to apply control theory to the treatment of disease, as mathematical models of the disease processes alone do not reveal possibly counterintuitive approaches to therapy. Optimal control methods are particularly well suited to the problem because they show the best that can be done within assumptions and provide a framework within which alternatives can be evaluated. The critical challenge is not to develop new theory but to apply what we know in a reasoned manner. Choosing elements of cost functions, specifying available control variables, and most importantly, using credible, reliable models of pathogenic attack, direct effects of therapy, and immune system response must be the focus. Here, we demonstrate how numerical optimization of nonlinear models can be combined with neighboring-optimal feedback control of linear models to suggest single-and multi-agent therapies that enhance the natural response of the innate immune system. We also show that theory cannot be applied uncritically, that numbers and values make important differences. Ultimately, a combination of mathematics and empiricism can solve real problems and improve the quality of life.
